- Builds on existing partnership by further leveraging the
combined power of real-world data, real-world evidence and
privacy-preserving record linkage technology to help solve key
clinical trial challenges.
- Aims to increase trial participant diversity, improve study
design and operations, and advance patient experience and outcomes
– while saving time and money.
PINC AI™ Applied Sciences (PAS), a division of Premier, Inc.
(NASDAQ: PINC), and Datavant, the company that protects, connects
and delivers the world’s health data, announce the companies are
expanding their existing collaboration to help shape the future of
healthcare research, advance clinical trial operations, and
increase trial diversity and equity – aiming to accelerate the
development of novel therapies and products for improved patient
outcomes.
The organizations have been working together since September
2022 to compliantly link real-world data to deliver meaningful
insights that improve the quality of patient care. Through this new
and expanded effort, PAS will leverage Datavant’s trial
tokenization solution and data connectivity platform to link
clinical trial data and PAS real-world data and generate real-world
evidence that propels clinical research innovation. This will
provide deeper insights into the benefits and risks of medical
interventions in real-world settings within and beyond the
controlled environments of clinical trials.
Robust real-world evidence is becoming increasingly important
for pharma and medical device development. As an example, with the
passage of the Inflation Reduction Act (IRA) in August 2022,
real-world evidence is serving as an important tool for life
sciences and medical device companies striving to demonstrate the
value and comparative effectiveness of their products and help
patients get access to the therapies and interventions they need
faster.
“As life sciences and medical device companies continue to
bridge the gap between medical solutions development and real-world
application, leveraging real-world data for real-world evidence
generation has emerged as a game changer,” said Myla Maloney, Chief
Growth Officer, PINC AI™ Applied Sciences. “With Datavant, we are
taking our best-in-class, real-world PINC AI™ Healthcare Data
(PHD), securely linking it with other real-world datasets via
tokens and leveraging it specifically in the clinical trials space
to enable evidence-based decision making, which we believe can lead
to better patient experiences and outcomes and cost and time
savings.”
Today, a clinical trial for a chronic condition is utilizing
Datavant to link clinical trial patient data and PHD data to
understand the participants’ complete patient journey. By uniting
clinical trial data with real-world data contained in the PHD,
researchers are gaining insight into medication history, which can
be difficult to collect, as well as the ability to follow the
patients forward after the trial has ended, when oftentimes
patients are lost. The real-world evidence generated from the
linked data can be used to assess important long-term health
outcomes outside of the clinical trial, improve drug safety and
efficacy, and empower the healthcare industry to treat chronic care
conditions more effectively.
In another clinical trial, a sponsor is building a real-world
evidence control arm using PAS’ real-world data connected by
Datavant at the patient level while preserving patient privacy.
Utilizing real-world data/real-world evidence derived from patients
on a standard of care may eliminate the need for researchers to
construct a separate control arm, which can decrease the duration
and cost of the clinical trial. The real-world evidence control arm
is also helping to improve the patient experience and outcomes by
enabling all study participants to partake in the treatment and its
potential benefits rather than a placebo, thereby increasing their
access to medical care.
In addition to these active trials, PAS’ linkable datasets are
being utilized by life sciences and medical device companies and
health systems to find diverse trial candidates and identify trial
sites – both of which have a critical impact on bringing new
solutions to market.
“Ever since launching our trial tokenization offering in 2019,
Datavant has held that linking clinical trial data and real-world
data has incredible promise to accelerate drug development, improve
the safety and efficacy of treatments, and lead to better patient
outcomes,” said Tal Rosenberg, President and GM, Life Sciences,
Ecosystem and Public Sector at Datavant. “We’ve now tokenized over
100 clinical trials, and we’re excited to broaden our work with PAS
and accelerate innovation with connected data.”
About PINC AI™ Applied Sciences (PAS)
PAS is a trusted leader in accelerating healthcare improvement
through services, data and scalable solutions, spanning the
continuum of care and enabling sustainable innovation and rigorous
research. These services and real-world data are valuable resources
for the pharmaceutical, device and diagnostic industries, academia,
federal and national healthcare agencies, as well as hospitals and
health systems. Since 2000, PAS researchers have produced more than
1,000 publications which appear in 264 scholarly, peer-reviewed
journals, covering a wide variety of topics, and conduct
population-based analyses of drugs, devices, treatments, disease
states, epidemiology, resource utilization, healthcare economics
and clinical outcomes.
About the PINC AI™ Platform
PINC AI™ is the technology and services platform of Premier,
Inc. (NASDAQ: PINC). With more than 20 years’ worth of cost,
quality and operational data gleaned from 45 percent of U.S.
hospital discharges, 2.7 billion hospital outpatient and clinic
encounters and 177 million physician office visits, the PINC AI™
platform provides actionable intelligence to help improve outcomes,
support improved financial performance and enable success in new,
alternative payment models. PINC AI™ incorporates the 100 Top
Hospitals ® Program that inspires hospital and health system
leaders to pursue higher performance and deliver added value to
their patients and communities. PINC AI™ offerings rely on advanced
analytics to identify improvement opportunities; support
award-winning Strategic Collaboratives for value-based care,
maternal and infant health, workforce innovation, and health
equity; and consulting services for clinical and operational
design, and workflow solutions to hardwire sustainable change. The
PINC AI™ platform is also the data engine powering Premier’s newest
brands – Remitra® and Contigo Health®. With a leading network of
provider organizations, the PINC AI™ platform accelerates ingenuity
and serves as a large-scale innovation catalyst in healthcare. PINC
AI™ offerings and capabilities can be followed on X (formerly
Twitter) and LinkedIn.
About Datavant
Datavant’s mission is to make the world’s health data secure,
accessible, and usable. Datavant is a data logistics company for
healthcare whose products and solutions enable organizations to
move and connect data securely.
Through proprietary technology, the world’s most robust
healthcare network, and value-added services we protect, connect,
and deliver the world’s health data. Datavant enables more than 60
million healthcare records to move between thousands of
organizations, more than 70,000 hospitals and clinics, 70 percent
of the 100 largest health systems, and an ecosystem of 500+
real-world data partners.
To learn more about Datavant, visit datavant.com.
About Datavant Connect
Datavant Connect is a platform for secure, compliant real-world
data connectivity. The platform enables organizations to tokenize
data, find and assess potential data partners, and connect datasets
at the individual level while preserving patient privacy. The
backbone of the platform is tokenization technology that uses
personally identifiable information (PII) to create encrypted
tokens, which are unique, irreversible, and site-specific keys that
can match individual patient records within and across
datasets.
Premier, Inc. Forward-Looking Statements
Statements made in this release that are not statements of
historical or current facts, including but not limited to those
related to Premier’s ability to advance its long-term strategies
and develop innovations for and transform healthcare and to
accelerate healthcare improvement, and the intended or expected
performance or utility of Premier’s and PINC AI’s products and
services, are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may involve known and unknown risks,
uncertainties, and other factors that may cause performance or
achievements to be materially different from historical results or
from any future performance or achievements expressed or implied by
such forward-looking statements. Accordingly, readers should not
place undue reliance on any forward-looking statements. More
information on risk factors relating to Premier and its products
and services is included from time to time in the “Cautionary Note
Regarding Forward-Looking Statements,” “Risk Factors,” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” sections of Premier’s periodic filings with
the SEC, which are also made available on Premier’s website at
investors.premierinc.com. Forward-looking statements speak only as
of the date they are made, and Premier undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information or future events that occur after
that date, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213685159/en/
PINC AI™ Applied Sciences Contact:
public_relations@premierinc.com Datavant Contact:
pr@datavant.com
Premier (NASDAQ:PINC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Premier (NASDAQ:PINC)
Historical Stock Chart
From Sep 2023 to Sep 2024